Milan J, Niemczyk K, Kus-Likiewicz M (2022) Treasure on the earthgold nanoparticles and their biomedical applications
Simple math, consistent dosing
Diabetes Obes Metab 2022;25:1835
Mar 19, 2026, 12:04 ET Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment * with Wegovy HD (~19% regardless of whether patients stayed on treatment ** ) in the STEP UP trial 1 In the STEP UP trial, about one in three trial participants taking Wegovy HD achieved 25% weight loss or higher 1 This approval for Wegovy further expands its already robust label inclusive of multiple formulations, including Wegovy pill, and indications not available with other GLP-1 weight loss medicines PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy , Wegovy HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial
Every product is precisely formulated by a team of nutritional therapists based on the latest science
As you eat less, your body uses stored energy
.png)
